Unbiased phenotypic drug screening shows potent antitumor activity of the small molecule survivin inhibitor YM155 in renal cell carcinoma (DGU 2026) - Oct 15, 2026 - Abstract #V38-05; Pres time: Sep 18, 2026; 10:40 AM - 10:50 AM; Location: Room 19; "In conclusion, this study provides evidence for acute and long-term antitumoral effects of the survivin inhibitor YM155 through a cell cycle arrest in early S-phase. This finding argues in favour of targeting the cell cycle machinery as a promising therapeutic concept in advanced RCC."
Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • DUSP5 • VHL
|
|
P. Reimold 1; I. Schindler 2; A. Kaczorowski 2; A. Duensing 3; J. Huber 1; S. Duensing 2
|